RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers
With great interest we read the results of the pivotal French PIPOX trial [1]. The authors are to be congratulated for finishing the first phase I (3 + 3) dose-escalation trial assessing the maximum tolerated dose (MTD) of repetitive oxaliplatin-based pressurised intraperitoneal aerosol chemotherapy (PIPAC-oxaliplatin) in patients with unresectable peritoneal metastases of gastrointestinal cancers. After at least three months of systemic thera py before enrolment, patients in the PIPOX trial received four-to-six weekly intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2) followed by PIPAC-oxaliplatin at five planned dose levels (90–300 mg/m2 with increments of 50 mg/m2).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Koen P. Rovers, Robin J. Lurvink, Maarten J. Deenen, Ignace H.J.T. de Hingh Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | France Health | Gastroenterology | Laparoscopy | Peritoneal Cancer | Study